| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8829070 | Prostate International | 2017 | 5 Pages |
Abstract
The exact role of 68Ga-PSMA-PET/CT in primary prostate cancer is not yet entirely clear. It has an improved detection rate for smaller lesions and may be able to identify nodal or distant metastatic disease at an earlier stage. While still experimental, there may also be value in combining 68Ga-PSMA-PET to multiparametric magnetic resonance imaging for staging of intraprostatic disease. To date, 68Ga-PSMA-PET/CT has been shown to have considerable clinical value and to impact treatment selection for patients with prostate cancer. Still in its infancy, the results of future clinical trials will be excitedly awaited.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Urology
Authors
Cristian Udovicich, Marlon Perera, Michael S. Hofman, Shankar Siva, Andres Del Rio, Declan G. Murphy, Nathan Lawrentschuk,